Molecular Mechanism of Selective Binding of NMS-P118 to PARP-1 and PARP-2: A Computational Perspective.
NMS-P118
PARP
alanine scanning
binding free energy
interaction entropy
selectivity
Journal
Frontiers in molecular biosciences
ISSN: 2296-889X
Titre abrégé: Front Mol Biosci
Pays: Switzerland
ID NLM: 101653173
Informations de publication
Date de publication:
2020
2020
Historique:
received:
24
02
2020
accepted:
13
03
2020
entrez:
7
5
2020
pubmed:
7
5
2020
medline:
7
5
2020
Statut:
epublish
Résumé
The nuclear protein poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors have been proven effective to potentiate both chemotherapeutic agents and radiotherapy. However, a major problem of most current PARP inhibitors is their lack of selectivity for PARP-1 and its closest isoform PARP-2. NMS-P118 is a highly selective PARP inhibitor that binds PARP-1 stronger than PARP-2 and has many advantages such as excellent pharmacokinetic profiles. In this study, molecular dynamics (MD) simulations of NMS-P118 in complex with PARP-1 and PARP-2 were performed to understand the molecular mechanism of its selectivity. Alanine scanning together with free energy calculation using MM/GBSA and interaction entropy reveal key residues that are responsible for the selectivity. Although the conformation of the binding pockets and NMS-P118 are very similar in PARP-1 and PARP-2, most of the hot-spot residues in PARP-1 have stronger binding free energy than the corresponding residues in PARP-2. Detailed analysis of the binding energy shows that the 4'4-difluorocyclohexyl ring on NMS-P118 form favorable hydrophobic interaction with Y889 in PARP-1. In addition, the H862 residue in PARP-1 has stronger binding free energy than H428 in PARP-2, which is due to shorter distance and stronger hydrogen bonds. Moreover, the negatively charged E763 residue in PARP-1 forms stronger electrostatic interaction energy with the positively charged NMS-P118 than the Q332 residue in PARP-2. These results rationalize the selectivity of NMS-P118 and may be useful for designing novel selective PARP inhibitors.
Identifiants
pubmed: 32373627
doi: 10.3389/fmolb.2020.00050
pmc: PMC7179655
doi:
Types de publication
Journal Article
Langues
eng
Pagination
50Informations de copyright
Copyright © 2020 Wang, Cong, Li, Bao, Qi and Zhang.
Références
J Chem Theory Comput. 2018 Mar 13;14(3):1772-1780
pubmed: 29406753
J Chem Theory Comput. 2008 May 9;4(6):869-876
pubmed: 19936324
Bioinformatics. 2006 Jun 1;22(11):1335-42
pubmed: 16522669
Phys Chem Chem Phys. 2018 May 30;20(21):14450-14460
pubmed: 29785435
Curr Med Chem. 2012;19(23):3907-21
pubmed: 22788767
Br J Pharmacol. 2018 Jan;175(2):192-222
pubmed: 28213892
J Comput Chem. 2007 Feb;28(3):644-54
pubmed: 17195156
Phys Chem Chem Phys. 2014 Oct 28;16(40):22035-45
pubmed: 25205360
Phys Chem Chem Phys. 2020 Mar 21;22(11):6136-6144
pubmed: 32124883
J Chem Inf Model. 2008 Jul;48(7):1396-410
pubmed: 18570371
Mol Cell. 2010 Jul 9;39(1):8-24
pubmed: 20603072
J Med Chem. 2015 Sep 10;58(17):6875-98
pubmed: 26222319
Biochemistry. 1994 Dec 20;33(50):15178-89
pubmed: 7999778
Free Radic Biol Med. 2009 Jul 1;47(1):13-26
pubmed: 19362586
J Chem Inf Model. 2017 May 22;57(5):1112-1122
pubmed: 28406301
Mol Cancer Ther. 2007 Mar;6(3):945-56
pubmed: 17363489
Proteins. 2004 May 1;55(2):383-94
pubmed: 15048829
Eur J Pharmacol. 1999 Nov 3;383(3):259-66
pubmed: 10594317
J Chem Inf Model. 2013 Sep 23;53(9):2376-89
pubmed: 23952683
J Comput Chem. 2004 Jul 15;25(9):1157-74
pubmed: 15116359
Nat Rev Mol Cell Biol. 2006 Jul;7(7):517-28
pubmed: 16829982
EMBO Rep. 2008 Nov;9(11):1094-100
pubmed: 18927583
Clin Cancer Res. 2013 Sep 15;19(18):5003-15
pubmed: 23881923
Science. 2017 Mar 17;355(6330):1152-1158
pubmed: 28302823
Clin Cancer Res. 2007 May 1;13(9):2728-37
pubmed: 17473206
Trends Mol Med. 2008 Apr;14(4):169-78
pubmed: 18353725
Eur J Med Chem. 2011 Sep;46(9):3845-50
pubmed: 21680063
IUCrJ. 2016 Jan 01;3(Pt 1):51-60
pubmed: 26870381
Sci Rep. 2017 Dec 18;7(1):17708
pubmed: 29255159
Bioessays. 2004 Aug;26(8):882-93
pubmed: 15273990
J Chem Theory Comput. 2015 Aug 11;11(8):3696-713
pubmed: 26574453
Nucleic Acids Res. 2000 Jan 1;28(1):235-42
pubmed: 10592235
Nature. 1987 Aug 6-12;328(6130):551-4
pubmed: 3302725
Biophys J. 2012 Feb 8;102(3):407-16
pubmed: 22325262
Acta Crystallogr D Biol Crystallogr. 2014 Oct;70(Pt 10):2740-53
pubmed: 25286857
Hum Pathol. 2005 Jul;36(7):724-31
pubmed: 16084940
Annu Rev Biophys Biophys Chem. 1989;18:431-92
pubmed: 2660832
Hered Cancer Clin Pract. 2015 Jan 17;13(1):4
pubmed: 25606064
J Am Chem Soc. 2016 May 4;138(17):5722-8
pubmed: 27058988
Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17079-84
pubmed: 18971340
Drug Resist Updat. 2009 Dec;12(6):153-6
pubmed: 19939726
Biochim Biophys Acta. 2014 Aug;1846(1):201-15
pubmed: 25026313
Br J Radiol. 2008 Oct;81 Spec No 1:S2-5
pubmed: 18819994
J Med Chem. 2004 Oct 21;47(22):5467-81
pubmed: 15481984
Pain. 1988 Apr;33(1):87-107
pubmed: 2837713
Acc Chem Res. 2000 Dec;33(12):889-97
pubmed: 11123888